In utero exposure to venlafaxine, a serotonin-norepinephrine reuptake inhibitor, increases cardiac anomalies and alters placental and heart serotonin signaling in the rat

详细信息    查看全文

• 作者：Laetitia Laurent ; Chunwei Huang ; Sheila R. Ernest ; Anick Berard ; Cathy Vaillancourt and Barbara F. Hales
• 刊名：Birth Defects Research Part A: Clinical and Molecular Teratology
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：106
• 期：12
• 页码：1044-1055
• 全文大小：486K
• ISSN：1542-0760

文摘

Human studies are inconsistent with respect to an association between treatment with selective serotonin and serotonin–norepinephrine reuptake inhibitors (SSRI/SNRIs) and an increase in the incidence of congenital heart defects. Here we tested the hypothesis that in utero exposure to venlafaxine, a highly prescribed SNRI, increases the incidence of fetal heart defects and alters placental and fetal heart serotonin signaling in the rat.